

Art Unit: 1651

CLMPTO 12/22/04 SLW

Claims 1-7 (CANCELED)

- 10. (Amended) The method of claim 8, wherein the effective amount of the gp130 receptor ligand is an amount from about 5ng/ml to about 200 ng/ml.--

Claim 11 (CANCELED)

- 12. (Amended) The method of claim 8, wherein the effective amount of the gp130 receptor ligand is cardiotrophin, an oncostatin M, a ciliary neuronotrophic factor, or an interleukin-6.--
- 13. (Amended) The method of claim 8, wherein the growth factor is one or more of a TGF $\alpha$ , a FGF-2, a FGF-9, a TIMP-1, or a TIMP-2.--
- 14. (Amended) The method of claim 8, wherein the growth factor is TGF $\alpha$ , a FGF-2, or FGF-9 and the effective amount of TGF $\alpha$ , a FGF-2, or FGF-9 is an amount from about 1 ng/ml to about 100 ng/ml.--

Claim 15 (CANCELED)

- 16. (Amended) The method of claim 8, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of TIMP-1 or TIMP-2 is an amount from about 200 ng/ml to about 2  $\mu$ g/ml.--

Claim 17 (CANCELED)

- 18. (Amended) The method of claim 8, wherein the gp130 receptor ligand is a polypeptide comprising a sequence identical to a naturally occurring human gp 130 receptor ligand.--
- 19. (Amended) The method of claim 9, wherein the leukemia inhibitory factor is a polypeptide comprising a sequence identical to a naturally occurring human leukemia inhibitory factor.--
- 20. (Amended) The method of claim 8, wherein the growth factor is a polypeptide comprising a sequence identical to a naturally occurring human growth factor.--

Application/Control Number: 09/980,853

Page 3

Art Unit: 1651

Claim 21 (CANCELED)